T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures - PubMed (original) (raw)
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures
A Knuth et al. Proc Natl Acad Sci U S A. 1984 Jun.
Abstract
The cytotoxic reactivity of lymphocytes for autologous melanoma cells was studied in a group of 13 melanoma patients. No cytotoxicity was observed with lymphocytes freshly isolated from peripheral blood or with lymphocytes cocultured for 7 days with autologous melanoma cells. Growth of lymphocytes previously sensitized with autologous melanoma in vitro in interleukin 2 (IL-2)-containing medium, however, resulted in cytotoxic reactivity for autologous melanoma in 7/13 patients. The reactivity of IL-2-dependent lymphocytes for autologous melanoma was particularly striking in one patient (A.V.) who has had an unexpectedly favorable clinical course and, because of their consistently high reactivity, AV lymphocytes were selected for detailed specificity analysis. After 2-3 weeks in culture in IL-2-containing medium, AV lymphocytes were cytolytic for autologous melanoma cells but not autologous Epstein-Barr virus-transformed B cells, autologous fibroblasts, or allogeneic tumor targets. Specificity of autologous melanoma reactivity was confirmed by competitive inhibition assays. The IL-2-dependent AV lymphocytes formed rosettes with sheep erythrocytes and expressed OKT 3 and Ia antigens. After longer periods of culture, AV lymphocytes were found to react with a wider range of target cells, and repeated attempts to isolate cultures with restricted reactivity to autologous melanoma by resensitization with autologous melanoma and limiting-dilution techniques were unsuccessful. The restricted reactivity of early cultures could be preserved, however, in frozen storage, but shifted again toward broader reactivity after several weeks in culture. The recognition of cytotoxic T cells with initial restricted reactivity for autologous melanoma suggests reinvestigation of the question of specific cellular immunity to human cancer.
Similar articles
- Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma.
Anichini A, Fossati G, Parmiani G. Anichini A, et al. Int J Cancer. 1985 May 15;35(5):683-9. doi: 10.1002/ijc.2910350518. Int J Cancer. 1985. PMID: 3158614 - Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K, Tilden AB, Balch CM. Itoh K, et al. Cancer Res. 1986 Jun;46(6):3011-7. Cancer Res. 1986. PMID: 3486040 - Tumor-specific T-cell clones recognize different protein determinants of autologous human malignant melanoma cells.
Notter M, Schirrmacher V. Notter M, et al. Int J Cancer. 1990 May 15;45(5):834-41. doi: 10.1002/ijc.2910450508. Int J Cancer. 1990. PMID: 2159436 - Lymphocyte mediated reactivity against malignant melanoma detected by a microcytotoxicity assay employing technetium-99m labeled target cells.
Gillespie GY, Barth RF. Gillespie GY, et al. Cancer. 1978 Jun;41(6):2174-82. doi: 10.1002/1097-0142(197806)41:6<2174::aid-cncr2820410616>3.0.co;2-m. Cancer. 1978. PMID: 350374 Review. No abstract available.
Cited by
- Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Passaro A, et al. Cell. 2024 Mar 28;187(7):1617-1635. doi: 10.1016/j.cell.2024.02.041. Cell. 2024. PMID: 38552610 Free PMC article. Review. - Recent Advances in Molecular Mechanisms of Cancer Immunotherapy.
Kciuk M, Yahya EB, Mohamed Ibrahim Mohamed M, Rashid S, Iqbal MO, Kontek R, Abdulsamad MA, Allaq AA. Kciuk M, et al. Cancers (Basel). 2023 May 11;15(10):2721. doi: 10.3390/cancers15102721. Cancers (Basel). 2023. PMID: 37345057 Free PMC article. Review. - T Cell Based Immunotherapy for Cancer: Approaches and Strategies.
Want MY, Bashir Z, Najar RA. Want MY, et al. Vaccines (Basel). 2023 Apr 13;11(4):835. doi: 10.3390/vaccines11040835. Vaccines (Basel). 2023. PMID: 37112747 Free PMC article. Review. - Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1): A Promising Cancer Testis Antigen.
Bai R, Yuan C. Bai R, et al. Aging Dis. 2022 Jul 11;13(4):1267-1277. doi: 10.14336/AD.2021.1207. eCollection 2022 Jul 11. Aging Dis. 2022. PMID: 35855340 Free PMC article. Review. - Chemokines network in bone metastasis: Vital regulators of seeding and soiling.
Sharma G, Pothuraju R, Kanchan RK, Batra SK, Siddiqui JA. Sharma G, et al. Semin Cancer Biol. 2022 Nov;86(Pt 3):457-472. doi: 10.1016/j.semcancer.2022.02.003. Epub 2022 Feb 3. Semin Cancer Biol. 2022. PMID: 35124194 Free PMC article. Review.
References
- Proc Natl Acad Sci U S A. 1977 Oct;74(10):4587-90 - PubMed
- Nature. 1977 Jul 14;268(5616):154-6 - PubMed
- Proc Natl Acad Sci U S A. 1978 Oct;75(10):5122-6 - PubMed
- Int J Cancer. 1979 Jul 15;24(1):34-44 - PubMed
- J Exp Med. 1979 Sep 19;150(3):564-79 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical